Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, Chiang Y, Ehrlich JS, Erickson S, Hanley WD, Horvath J, Maass KF, Singh N, Tang F, Barteselli G. Campochiaro PA, et al. Among authors: barteselli g. Ophthalmology. 2019 Aug;126(8):1141-1154. doi: 10.1016/j.ophtha.2019.03.036. Epub 2019 Apr 1. Ophthalmology. 2019. PMID: 30946888 Free article. Clinical Trial.
Reply.
Campochiaro PA, Maass KF, Singh N, Barteselli G. Campochiaro PA, et al. Among authors: barteselli g. Ophthalmology. 2019 Nov;126(11):e88-e89. doi: 10.1016/j.ophtha.2019.06.020. Ophthalmology. 2019. PMID: 31635711 No abstract available.
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C; all Archway Investigators. Holekamp NM, et al. Among authors: barteselli g. Ophthalmology. 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016. Epub 2021 Sep 29. Ophthalmology. 2022. PMID: 34597713 Free article. Clinical Trial.
Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration.
Bantseev V, Horvath J, Barteselli G, Ranade S, Maia M, Yadav DB, Schuetz C, Shelton A, Booler HS. Bantseev V, et al. Among authors: barteselli g. Toxicol Pathol. 2021 Apr;49(3):663-672. doi: 10.1177/0192623320968079. Epub 2020 Nov 18. Toxicol Pathol. 2021. PMID: 33205714
Refill-Exchange Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Trial Experience.
Khanani AM, Graff JM, Marcus DM, Wykoff CC, Jhaveri CD, Barteselli G, Malhotra VK, Menezes AR, Callaway NF. Khanani AM, et al. Among authors: barteselli g. Ophthalmic Surg Lasers Imaging Retina. 2022 May;53(5):257-265. doi: 10.3928/23258160-20220412-01. Epub 2022 May 1. Ophthalmic Surg Lasers Imaging Retina. 2022. PMID: 35575741 Free article.
73 results